Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
Authors:
- T YoshiokaTYT Yoshioka
- S KatoSKS Kato
- S TakahashiSTS Takahashi
Open Access
- 17 November 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (12) , 1972-1977
Abstract
Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11. Therefore, we designed a sequential combination, in which CPT-11 infusion was given on day 1 and S-1 was given orally at 80 mg m−2 per day on days 3–16 every 3 weeks. Twelve patients entered the phase I study, and the recommended doses were determined as a CPT-11 dose of 150 mg m−2 and an S-1 dose of 80 mg m−2. In all, 36 patients entered the phase II study, of whom 4 and 16 had complete and partial responses. The overall response rate was 55.6% (95% confidence interval, 38.1–72.1%), and median progression-free survival was 7.7 months (95% confidence interval, 4.8–12.6 months). Grade 3 neutropenia was the most common haematological toxicity and occurred in 6.5% of 215 treatment courses. Grade 3 non-haematological toxicities included anorexia (1.4%) and diarrhoea (0.9%). There was no grade 4 toxicity of any kind. Our results suggest that this regimen is convenient, safe and promising, compared with conventional regimens for patients with metastatic colorectal cancer.Keywords
This publication has 30 references indexed in Scilit:
- Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancerAnnals of Oncology, 2006
- New approaches to prevent intestinal toxicity of irinotecan-based regimensCancer Treatment Reviews, 2004
- Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-AnalysisJournal of Clinical Oncology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II study of oral S‐1 for treatment of metastatic colorectal carcinomaCancer, 2004
- Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer PatientsJournal of Clinical Oncology, 2003
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Simultaneous Administration of CPT-11 and Fluorouracil: Alteration of the Pharmacokinetics of CPT-11 and SN-38 in Patients With Advanced Colorectal CancerJNCI: Journal of the National Cancer Institute, 1994